West Pharmaceutical Services (WST) Expected to Announce Earnings on Thursday

West Pharmaceutical Services (NYSE:WST) will likely be issuing its Q1 2026 results before the market opens on Thursday, April 23rd. Analysts expect the company to announce earnings of $1.68 per share and revenue of $779.6750 million for the quarter. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS. Parties may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, April 23, 2026 at 8:00 AM ET.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, February 12th. The medical instruments supplier reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.83 by $0.21. West Pharmaceutical Services had a net margin of 16.06% and a return on equity of 17.90%. The firm had revenue of $805.00 million during the quarter, compared to the consensus estimate of $795.70 million. During the same period in the previous year, the firm earned $1.82 earnings per share. West Pharmaceutical Services’s revenue was up 7.5% compared to the same quarter last year. On average, analysts expect West Pharmaceutical Services to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

West Pharmaceutical Services Price Performance

West Pharmaceutical Services stock opened at $278.12 on Tuesday. West Pharmaceutical Services has a 1 year low of $199.89 and a 1 year high of $322.34. The firm has a 50 day moving average price of $249.50 and a 200 day moving average price of $261.66. The company has a market cap of $20.05 billion, a price-to-earnings ratio of 40.96, a PEG ratio of 2.91 and a beta of 1.15. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.34 and a current ratio of 3.02.

West Pharmaceutical Services announced that its board has initiated a share repurchase plan on Tuesday, February 17th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the medical instruments supplier to repurchase up to 5.6% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board believes its shares are undervalued.

West Pharmaceutical Services Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 6th. Investors of record on Wednesday, April 29th will be issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Wednesday, April 29th. West Pharmaceutical Services’s payout ratio is presently 12.96%.

Wall Street Analyst Weigh In

WST has been the subject of a number of recent analyst reports. Barclays boosted their target price on shares of West Pharmaceutical Services from $265.00 to $275.00 and gave the company an “equal weight” rating in a report on Tuesday, April 14th. Evercore reduced their price target on shares of West Pharmaceutical Services from $390.00 to $320.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 3rd. Jefferies Financial Group reaffirmed a “buy” rating and set a $295.00 price target on shares of West Pharmaceutical Services in a research report on Tuesday, February 10th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of West Pharmaceutical Services in a research report on Friday, January 9th. Finally, UBS Group reaffirmed a “buy” rating and set a $340.00 price target on shares of West Pharmaceutical Services in a research report on Friday, February 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, West Pharmaceutical Services has a consensus rating of “Moderate Buy” and a consensus target price of $315.67.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Caerus Investment Advisors LLC grew its holdings in West Pharmaceutical Services by 6.2% during the 4th quarter. Caerus Investment Advisors LLC now owns 1,035 shares of the medical instruments supplier’s stock valued at $285,000 after purchasing an additional 60 shares in the last quarter. Aptus Capital Advisors LLC grew its holdings in West Pharmaceutical Services by 5.5% during the 4th quarter. Aptus Capital Advisors LLC now owns 905 shares of the medical instruments supplier’s stock valued at $249,000 after purchasing an additional 47 shares in the last quarter. Knollwood Investment Advisory LLC acquired a new stake in West Pharmaceutical Services during the 3rd quarter valued at $220,000. Ausdal Financial Partners Inc. acquired a new stake in West Pharmaceutical Services during the 3rd quarter valued at $220,000. Finally, Brooklyn Investment Group grew its holdings in West Pharmaceutical Services by 81.3% during the 3rd quarter. Brooklyn Investment Group now owns 816 shares of the medical instruments supplier’s stock valued at $214,000 after purchasing an additional 366 shares in the last quarter. 93.90% of the stock is owned by institutional investors and hedge funds.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.